In atherosclerosis, discrimination between stable and vulnerable plaques is of particular clinical importance. For imaging purposes, the intraplaque macrophage content can be used as a distinctive feature and a specific marker of vulnerable plaques. Thus, MRI of macrophages using contrast-enhancing agents can help to discriminate between these plaques.
Introduction
In atherosclerosis, discrimination between stable and vulnerable plaques is of particular clinical importance. For imaging purposes, the intraplaque macrophage content can be used as a distinctive feature and a specific marker of vulnerable plaques. Thus, MRI of macrophages using contrast-enhancing agents can help to discriminate between these plaques. 1 Recently, synthetic particles that mimic human high density lipoproteins (HDL) were proposed as a delivery vehicle for Gd-based contrast agents (GBCA). 2, 3 However, native HDL are not normally uptaken by macrophages, leading to the need for targeting moieties to image plaques. 4 To avoid the pitfalls and complications associated with these moieties, new approaches are needed.
In this study, a naturally occurring modification in the major HDL protein, apolipoprotein (apo) A-I, was exploited as a natural way to target GBCA-HDL to macrophages. We also tested if fully functional GBCA-HDL can be generated using synthetic apo A-I peptides in place of native apo A-I. Methods Self-assembled paramagnetic and fluorescent HDL containing either the oxidized or unmodified apo A-I protein were synthesized using the molar ratio of 1:65:25:38:2 for apo A-I:DMPC:DMPG:PE-DTPA-Gd:rho B-PE. Alternatively, a 1:1 mixture of either oxidized or unmodified 22-mer peptides that correspond to amphipathic apo A-I helixes 4 (H4) and 6 (H6) was used. The obtained particles of discoidal morphology with the mean size of 12 nm were characterized by a variety of biophysical methods, including electron microscopy. Fluorescence and MRI studies of in vitro macrophage uptake were carried out using J774 macrophages. The abdominal aortas of either apo E-deficient atherosclerotic mice kept on a Western diet or wild type mice kept on a normal chow diet were imaged using a 3.0T MRI system before and 24 h after injection of the synthesized contrast agents. In vivo MRI data were complemented by immunohistology and fluorescence microscopy.
Results
Specific oxidation of apo A-I or its peptides does not affect the size, composition, and relaxivity properties of GBCA-HDL but increases the in vitro macrophage uptake by 2-3 times and significantly improves atherosclerotic plaque detection in vivo (Fig. 1) . At 24 h post-injection of 0.05 mmol Gd/kg GBCA-HDL containing oxidized apo A-I or its peptides, the atherosclerotic wall/muscle normalized enhancement ratios were 90% and 120%, respectively, while those of GBCA-HDL containing their unmodified counterparts were 35% and 45%, respectively. Immunohistology and confocal fluorescence microscopy confirm the accumulation of GBCA-HDL containing oxidized apo A-I or its peptides in intraplaque macrophages (Fig. 1) . Conclusions Specific oxidation of apo A-I targets GBCA-HDL to macrophages in vitro and in vivo. Synthetic peptides can functionally replace the native apo A-I protein in HDL, encouraging the further development of these agents with broad application in cardiology, oncology and other diseases, where macrophage imaging has important diagnostic and prognostic value.
